MX348567B - Proteina de fusion que tiene actividad de factor vii. - Google Patents

Proteina de fusion que tiene actividad de factor vii.

Info

Publication number
MX348567B
MX348567B MX2012013807A MX2012013807A MX348567B MX 348567 B MX348567 B MX 348567B MX 2012013807 A MX2012013807 A MX 2012013807A MX 2012013807 A MX2012013807 A MX 2012013807A MX 348567 B MX348567 B MX 348567B
Authority
MX
Mexico
Prior art keywords
fusion protein
factor vii
fvii
vii activity
transferrin
Prior art date
Application number
MX2012013807A
Other languages
English (en)
Other versions
MX2012013807A (es
Inventor
Lee Ho-Soon
Lee Bong-Yong
Song In-Young
Kim Hun-Taek
Park Mahn-Hoon
Jung Lim Yun
Lee Ji-Hye
Yeon Son Seo
Kim Min-Sun
Original Assignee
Tiumbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tiumbio Co Ltd filed Critical Tiumbio Co Ltd
Publication of MX2012013807A publication Critical patent/MX2012013807A/es
Publication of MX348567B publication Critical patent/MX348567B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una proteína de fusión que comprende factor VII (FVII) y transferrina de conformidad con la presente invención, tiene una actividad específica mejorada de FVII en comparación con las proteínas de fusión de FVII existentes que comprenden otras parejas de fusión distintas a la transferrina, y por lo tanto se puede usar de manera efectiva en una terapia que usa FVII.
MX2012013807A 2010-06-04 2011-06-07 Proteina de fusion que tiene actividad de factor vii. MX348567B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100052719 2010-06-04
PCT/KR2011/004131 WO2011152694A2 (en) 2010-06-04 2011-06-07 Fusion protein having factor vii activity

Publications (2)

Publication Number Publication Date
MX2012013807A MX2012013807A (es) 2012-12-17
MX348567B true MX348567B (es) 2017-06-20

Family

ID=45067214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013807A MX348567B (es) 2010-06-04 2011-06-07 Proteina de fusion que tiene actividad de factor vii.

Country Status (13)

Country Link
US (2) US9644197B2 (es)
EP (1) EP2576625B1 (es)
JP (2) JP6143297B2 (es)
KR (1) KR101331101B1 (es)
CN (2) CN107188970A (es)
AU (1) AU2011262494B2 (es)
BR (1) BR112012030941A2 (es)
CA (1) CA2801223C (es)
ES (1) ES2676874T3 (es)
MX (1) MX348567B (es)
RU (1) RU2585231C2 (es)
WO (1) WO2011152694A2 (es)
ZA (1) ZA201300066B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348567B (es) 2010-06-04 2017-06-20 Tiumbio Co Ltd Proteina de fusion que tiene actividad de factor vii.
ES2630031T3 (es) * 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
US20160060612A1 (en) * 2013-02-25 2016-03-03 Sk Chemicals Co., Ltd. Method of Isolating and Purifying Fusion Protein Comprising Factor VII
KR102058864B1 (ko) 2013-12-16 2019-12-24 주식회사 티움바이오 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물
EP3351263A1 (en) 2017-01-20 2018-07-25 Universitätsklinikum Hamburg-Eppendorf Pharmaceutical preparation for treating or preventing tissue adhesion
CA3073317A1 (en) 2017-08-18 2019-02-21 Neutrolis Therapeutics, Inc. Engineered dnase enzymes and use in therapy
CN111315670B (zh) 2017-10-30 2021-11-26 松下知识产权经营株式会社 货架标签检测装置、货架标签检测方法、以及记录介质
KR20210072790A (ko) 2018-10-08 2021-06-17 뉴트롤리스 인코포레이티드 제조 및 치료를 위한 dnase 효소의 엔지니어링
US10988746B2 (en) * 2018-10-08 2021-04-27 Neutrolis, Inc. Manufacturing and engineering of DNASE enzymes for therapy
CN110218259B (zh) * 2019-06-24 2022-09-16 王跃驹 植物生产胰高血糖素样肽-1短肽与转铁蛋白的融合蛋白制造口服降糖胶囊的应用
CN110229237A (zh) * 2019-06-24 2019-09-13 王跃驹 植物生产口服epo与转铁蛋白融合蛋白胶囊的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
RU2278123C2 (ru) 2000-02-11 2006-06-20 Максиджен Холдингз Лтд. Молекулы, подобные фактору vii или viia
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
EP1427750B1 (en) * 2001-08-30 2010-12-08 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins
ES2355488T3 (es) * 2001-08-30 2011-03-28 Biorexis Technology, Inc. Proteína de fusión de tranferrina modificadas.
US7176278B2 (en) * 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
PT1549341E (pt) 2002-05-01 2009-05-29 Bayer Schering Pharma Ag Anticorpos dirigidos contra o factor tecidual como anticoagulantes
US20060130158A1 (en) * 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US20070072271A1 (en) * 2004-01-07 2007-03-29 Novo Nordisk Healthcare A/G Method for the production of recombinant proteins
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DK2004683T3 (en) * 2006-03-24 2016-08-22 Biogen Hemophilia Inc PC5 AS A FACTOR IX PROPEPTID PROCESSING ENZYM
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
US7943733B2 (en) 2007-12-20 2011-05-17 University Of Southern California Spacers to increase the expression of recombinant fusion proteins
WO2009158704A2 (en) 2008-06-27 2009-12-30 Duke University Therapeutic agents comprising elastin-like peptides
CN102647945B (zh) * 2009-12-08 2015-07-29 皇家飞利浦电子股份有限公司 用于校正示踪剂摄取测量结果的方法和校正系统
MX348567B (es) 2010-06-04 2017-06-20 Tiumbio Co Ltd Proteina de fusion que tiene actividad de factor vii.

Also Published As

Publication number Publication date
KR101331101B1 (ko) 2013-11-19
EP2576625B1 (en) 2018-04-25
RU2012157301A (ru) 2014-07-20
MX2012013807A (es) 2012-12-17
RU2585231C2 (ru) 2016-05-27
WO2011152694A3 (en) 2012-04-19
JP6143297B2 (ja) 2017-06-07
JP6422918B2 (ja) 2018-11-14
AU2011262494A2 (en) 2013-08-01
CN103068854A (zh) 2013-04-24
ES2676874T3 (es) 2018-07-25
CA2801223C (en) 2019-12-03
BR112012030941A2 (pt) 2017-06-06
AU2011262494B2 (en) 2016-01-21
US20130236945A1 (en) 2013-09-12
ZA201300066B (en) 2014-03-26
EP2576625A4 (en) 2013-11-06
US10696960B2 (en) 2020-06-30
AU2011262494A1 (en) 2013-01-24
JP2017000144A (ja) 2017-01-05
WO2011152694A2 (en) 2011-12-08
WO2011152694A8 (en) 2013-01-17
KR20110133454A (ko) 2011-12-12
US9644197B2 (en) 2017-05-09
CN107188970A (zh) 2017-09-22
US20160194622A1 (en) 2016-07-07
JP2013529914A (ja) 2013-07-25
EP2576625A2 (en) 2013-04-10
CA2801223A1 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
MX2012013807A (es) Proteina de fusion que tiene actividad de factor vii.
PH12017501417A1 (en) Anti-fap antibodies and methods of use
MX365612B (es) Polipeptidos de factor x modificados y usos de los mismos.
TN2014000438A1 (en) Anti-fcrn antibodies
EP2536821A4 (en) IMPROVING THE ACTIVITY OF PROTEINS REQUIRING AGGREGATE FE-S
MX2015011951A (es) Proteinas de fusion que comprenden partes de union a pdgf y vegf y metodos de uso de las mismas.
MX360741B (es) Constructos de polipéptidos y sus usos.
MX2013007168A (es) Anticuerpo anti-pcsk9 y metodos de uso.
IN2012DN05237A (es)
MX363788B (es) Métodos para la producción de polipéptidos procesados proteolíticamente.
MX2013008903A (es) Metodos de desarrollo de variantes de terpeno sintasa.
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
PT3434775T (pt) Proteína que tem atividade de nuclease, proteínas de fusão e utilizações das mesmas
PH12016500753A1 (en) Antibodies specific to fcrn
WO2012053823A3 (ko) 인자 ix 활성을 갖는 융합 단백질
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
PH12015501854A1 (en) Factor ix polypeptide formulations
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
WO2013006766A3 (en) Formulations that stabilize proteins
EP2496608A4 (en) FUSION PROTEIN SPECIFICALLY BINDING TO A CONSTANT REGION OF ANTIBODY, PREPARATION THEREFOR, AND METHOD OF ISOLATING ANTIBODY USING THE SAME
WO2013025846A3 (en) Transferrin-tumstatin fusion protein and methods for producing and using the same
WO2013059439A3 (en) Combination therapy comprising an mmp-14 binding protein
MX2016005572A (es) Uso de monensina para regular la glicosilacion de proteinas recombinantes.
IN2014DN04600A (es)
MX341733B (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.

Legal Events

Date Code Title Description
FG Grant or registration